Cosimo Di Raimondo

Dr. Cosimo Di Raimondo

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
CGCesarina Giallongo
Cesarina Giallongo
Daniele TibulloDaniele Tibullo
Daniele Tibullo
NPNunziatina L. Parrinello
Nunziatina L. Parrinello
PCPiera La Cava
Piera La Cava
Michelino Di RosaMichelino Di Rosa
Michelino Di Rosa
FRFrancesco Di Raimondo
Francesco Di Raimondo
Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

Verified
Journal Article
Open access
PDF file
EDEster Del Duca
Ester Del Duca
PMPaola Morelli
Paola Morelli
LBLuigi Bennardo
Luigi Bennardo
CRCosimo Di Raimondo
Cosimo Di Raimondo
Steven NisticòSteven Nisticò
Steven Nisticò
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting areas with a high density of apocrine glands and characterized by subcutaneous nodules that may evolve into fistulas with pus secretion. Methods: The aim of this review is to investigate all current knowledge on cytokine regulation in the pathogenesis of HS. A systematic literature research using the words “cytokine”, “interleukin”, “pathway”, and “hidradenitis suppurativa” was performed in PubMed/Medline and Scopus/Embase databases. A search of the clinicaltrials.gov website for interventional recruiting and completed trials including the term “hidradenitis suppurativa” was also performed up to August 2020. We will discuss the pathogenetic role of various cytokines in HS and potential therapeutic targets for this debilitating disease. Results: The pathophysiology underlying this complex condition has not been clearly defined. An upregulation of various cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin (IL)-1, IL-17, IL-23, and other molecules seems to be related to this inflammatory condition. Various cells, such as lymphocytes T Helper 1 and 17 and keratinocytes seem to be involved in the genesis of this condition. Conclusions: Several future studies and clinical trials are necessary in order to have new knowledge about HS and to properly treat this complex condition.

1 May 2019 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
RCRaffaele Dante Caposiena Caro
Raffaele Dante Caposiena Caro
MCMaria Vittoria Cannizzaro
Maria Vittoria Cannizzaro
EBElisabetta Botti
Elisabetta Botti
CRCosimo Di Raimondo
Cosimo Di Raimondo
EMEleonora Di Matteo
Eleonora Di Matteo
LBLuca Bianchi
Luca Bianchi

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
CVCalogero Vetro
Calogero Vetro
Alessandra RomanoAlessandra Romano
Alessandra Romano
IAIrene Amico
Irene Amico
CCConcetta Conticello
Concetta Conticello
GMGiovanna Motta
Giovanna Motta
FRFrancesco Di Raimondo
Francesco Di Raimondo
Many progresses have been done in the management of gastrointestinal (GI) lymphomas during last decades, especially after the discovery of Helicobacter pylori-dependent lymphoma development. The stepwise implementation of new endoscopic techniques, by means of echoendoscopy or double-balloon enteroscopy, enabled us to more precisely describe the endoscopic features of GI lymphomas with substantial contribution in patient management and in tailoring the treatment strategy with organ preserving approaches. In this review, we describe the recent progresses in GI lymphoma management from disease diagnosis to follow-up with a specific focus on the endoscopic presentation according to the involved site and the lymphoma subtype. Additionally, new or emerging endoscopic technologies that have an impact on the management of gastrointestinal lymphomas are reported. We here discuss the two most common subtypes of GI lymphomas: the mucosa-associated lymphoid tissue and the diffuse large B cell lymphoma. A general outline on the state-of-the-art of the disease and on the role of endoscopy in both diagnosis and follow-up will be performed.

17 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FLFlavia Lozzi
Flavia Lozzi
CRCosimo Di Raimondo
Cosimo Di Raimondo
CLCaterina Lanna
Caterina Lanna
LDLaura Diluvio
Laura Diluvio
SMSara Mazzilli
Sara Mazzilli
Elena CampioneElena Campione
Elena Campione
Photosensitivity induced by drugs is a widely experienced problem, concerning both molecule design and clinical practice. Indeed, photo-induced cutaneous eruptions represent one of the most common drug adverse events and are frequently an important issue to consider in the therapeutic management of patients. Phototoxicity and photoallergy are the two different pathogenic mechanisms involved in photosensitization. Related cutaneous manifestations are heterogeneous, depending on the culprit drug and subject susceptibility. Here we report an updated review of the literature with respect to pathogenic mechanisms of photosensitivity, clinical manifestations, patient management, and prediction and evaluation of drug-induced photosensitivity. We present and discuss principal groups of photosensitizing drugs (antimicrobials, nonsteroidal anti-inflammatory drugs, anti-hypertensives, anti-arrhythmics, cholesterol, and glycemia-lowering agents, psychotropic drugs, chemotherapeutics, etc.) and their main damage mechanisms according to recent evidence. The link between the drug and the cutaneous manifestation is not always clear; more investigations would be helpful to better predict drug photosensitizing potential, prevent and manage cutaneous adverse events and find the most appropriate alternative therapeutic strategy.

11 January 2024 in Environmental Research
Verified
Journal Article
Closed access
FAFabio Artosi
Fabio Artosi
gaetana Costanzagaetana Costanza
gaetana Costanza
MPMonia Di Prete
Monia Di Prete
VGVirginia Garofalo
Virginia Garofalo
FLFlavia Lozzi
Flavia Lozzi
Elena CampioneElena Campione
Elena Campione